Bakker Juliet Tammenoms
Bakker Juliet Tammenoms's purchase track record
How the stock did after each of Bakker Juliet Tammenoms's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/15/2024 | CBLL | $4.03M | -25.2% | -42.9% | -7.2% |
| 5/17/2024 | RXST | $305K | -13.0% | -25.7% | +10.7% |
| 2/12/2024 | RXST | $407K | +15.7% | +2.6% | +6.4% |
| 2/10/2023 | RXST | $6.00M | +79.1% | +119.7% | +9.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
CeriBell Gets FDA Clearance for New EEG Analysis Tools. CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.
Transaction History
| RXST | ▲ Buy | Grant | 37,037 | — | 6/17/2026 | View on chart |
| CBLL | ▲ Buy | Grant | 7,838 | $0 | 6/2/2026 | View on chart |
| CBLL | ▲ Buy | Grant | 8,828 | $0 | 6/10/2025 | View on chart |
| RXST | ▲ Buy | Grant | 10,752 | — | 6/3/2025 | View on chart |
| CBLL | ▲ Buy | Open Market | 237,234 | $4.0M | 10/15/2024 | View on chart |
| CBLL | ▼ Sell | Other | 2,140,600 | — | 10/15/2024 | View on chart |
| CBLL | ▲ Buy | Grant | 6,618 | $0 | 10/11/2024 | View on chart |
| RXST | ▲ Buy | Grant | 2,554 | — | 6/6/2024 | View on chart |
| RXST | ▲ Buy | Open Market | 5,000 | $305K | 5/17/2024 | View on chart |
| RXST | ▲ Buy | Open Market | 4,000 | $205K | 2/14/2024 | View on chart |
| RXST | ▲ Buy | Open Market | 4,000 | $202K | 2/12/2024 | View on chart |
| RXST | ▼ Sell | Other | 1,617 | $0 | 11/30/2023 | View on chart |
| RXST | ▼ Sell | Other | 693 | $0 | 11/30/2023 | View on chart |
| RXST | ▼ Sell | Other | 445,400 | $0 | 11/30/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 349,245 | $10.4M | 11/29/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 145,068 | $4.3M | 11/28/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 400,000 | $10.9M | 11/15/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 100,000 | $2.7M | 11/14/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 2,950 | $89K | 9/11/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 10,033 | $303K | 9/8/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 19,967 | $601K | 9/7/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 16,208 | $474K | 8/25/2023 | View on chart |
| RXST | ▼ Sell | Other | 416 | $0 | 8/24/2023 | View on chart |
| RXST | ▼ Sell | Other | 267,300 | $0 | 8/24/2023 | View on chart |
| RXST | ▼ Sell | Other | 970 | $0 | 8/24/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 14,651 | $426K | 8/18/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 18,484 | $556K | 8/17/2023 | View on chart |
| RXST | ▼ Sell | Other | 497,150 | $0 | 8/9/2023 | View on chart |
| RXST | ▼ Sell | Other | 32,950 | $0 | 8/9/2023 | View on chart |
| RXST | ▼ Sell | Other | 439 | $0 | 6/14/2023 | View on chart |
| RXST | ▼ Sell | Other | 1,022 | $0 | 6/14/2023 | View on chart |
| RXST | ▼ Sell | Other | 267,300 | $0 | 6/14/2023 | View on chart |
| RXST | ▲ Buy | Grant | 5,731 | $0 | 6/1/2023 | View on chart |
| RXST | ▼ Sell | Other | 497,150 | $0 | 5/26/2023 | View on chart |
| RXST | ▼ Sell | Other | 33,135 | $0 | 5/26/2023 | View on chart |
| RXST | ▲ Buy | Open Market | 480,000 | $6.0M | 2/10/2023 | View on chart |
| RXST | ▲ Buy | Grant | 10,349 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.